Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Eamonn S Molloy Clear advanced filters

  • A rare but often fatal viral disease has been reported in a number of patients treated with rituximab, but how the risk of this complication should affect prescription practices demands consideration of several important factors.

    • Leonard H. Calabrese
    • Eamonn S. Molloy
    News & Views
    Nature Reviews Rheumatology
    Volume: 5, P: 528-529

  • In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.

    • Eamonn S. Molloy
    • Leonard H. Calabrese
    News & Views
    Nature Reviews Rheumatology
    Volume: 5, P: 418-419

  • Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the central nervous system that is associated with several immunosuppressive therapies. In this Opinion article, Calabrese and colleagues propose a ranking of immunosuppressive agents based on their risk of PML to support a better-informed decision-making process.

    • Leonard H. Calabrese
    • Eamonn Molloy
    • Joseph Berger
    Reviews
    Nature Reviews Rheumatology
    Volume: 11, P: 119-123

  • Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterised by asthma, eosinophilia and vasculitis. Here, the authors describe a genome-wide association study of EGPA that reveals clinical and genetic differences between subgroups stratified by autoantibody status (ANCA).

    • Paul A Lyons
    • James E Peters
    • Kenneth G. C. Smith
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-13